The effect of selenium enrichment on baker's yeast proteomewas published in the January 4 Journal of Proteomics (http://www.ncbi.nlm.nih.gov/pubmed/22067702) by Karam El-Bayoumy et. al.from the Penn State College of Medicine in Hershey, Penn.
In the study, the use of regular yeast (RY) and selenium-enriched yeast (SEY) as a dietary supplement is of interest because the Nutritional Prevention of Cancer trial revealed that SEY, but not RY, decreased the incidence of prostate cancer. Using two-dimensional difference in gel electrophoresis (2D-DIGE)-tandem mass spectrometry (MS/MS) approach, the researchers performed proteomic analysis of RY and SEY to identify proteins that are differentially expressed as a result of selenium enrichment.
The expression profile of five of the proteins with validated or putative roles in the carcinogenesis process, and for which antibodies against human forms of the proteins are available commercially was verified by western analysis. This study provides evidence for the first time that SEY contains higher levels of Pyruvate Kinase, HSP70, and Elongation factor 2 and lower levels of Eukaryotic Translation Initiation Factor 5A-2 and Triosephosphate Isomerase than those found in RY. The quantitative measurements of these five proteins are often used as biomarkers in predicting and understanding carcinogenesis.
Paul A. Willis, chief executive officer and president of Cypress Systems, Inc. said, "We always believed that selenium form does make a difference and felt it is the reason why high-selenium yeast such as SelenoExcell has been effective in cancer prevention clinical trials and why other forms of selenium have not been effective in clinical trials.”
In addition, this new study by Penn State supports the work of J.L. Barger et. al. August 17, 2011 in Genes Nutr (http://www.ncbi.nlm.nih.gov/pubmed/21847681) where they found that only high-selenium yeast significantly reduced the expression of GADD45Bin the four tissues that were examined, and that high-selenium yeast was also found to reduce GADD45B protein levels in liver. This gene is a member of a group of genes whose transcript levels are increased following stressful growth arrest conditions and treatment with DNA-damaging agents. The function of this gene, or its protein product, is involved in the regulation of cell growth and apoptosis or cell death.
The expression profile of proteins, with validated or putative roles in the carcinogenesis process, is becoming an important biomarker for understanding carcinogenesis. These results show that gene expression profiling is a powerful technique capable of elucidating differences in the bioactivity of different forms of selenium.
Dr. Mark Whitacre, a selenium biochemist who is chief operating officer and chief science officer at Cypress Systems, adds, "We suspect that the advantage of SelenoExcell high-selenium yeast is because of its content of multiple forms of selenium, including some that are more direct acting in anti-carcinogenesis. This newly published study from Penn State researchers supports this hypothesis."
The flagship branded ingredient of Cypress Systems, SelenoExcell high selenium yeast, was previously selected as the sole intervention agent in a series of cancer prevention and health related trials. SelenoExcell is supported by a Clinical Trial Agreement with the Cancer Prevention Division of the National Cancer Institute. SelenoExcell has GRAS (Generally Recognized As Safe) status and used in several food categories. The evaluation was based on scientific procedures and the safety assessment criteria established by the U.S. Food and Drug Administration.
For more information about SelenoExcell and this study contact Paul A. Willis at 559.229.7850 or visit www.CypSystems.com.